Straits Times Index
3,390.78 +9.94 (+0.29%) Nikkei
27,543.39 -142.08 (-0.51%) Hang Seng
21,329.87 +31.17 (+0.15%) FTSE 100
7,864.71 +28.00 (+0.36%) BTC-USD
23,252.08 +374.56 (+1.64%) CMC Crypto 200
536.91 +10.95 (+2.08%)
GSK plc (GSK.L)
| Previous close | 1,461.00 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 10,464,897 |
| Market cap | 60.831B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 13.63 |
| EPS (TTM) | 1.09 |
| Earnings date | 26 Apr 2023 |
| Forward dividend & yield | 0.61 (4.25%) |
| Ex-dividend date | 23 Feb 2023 |
| 1y target est | N/A |
- PR Newswire Asia
GSK Singapore announces regulatory approval for Nucala (mepolizumab) in two additional eosinophil-driven diseases
GSK Singapore today announced that Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), has been approved for treatment in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and hypereosinophilic syndrome (HES)[1]. These new indications for mepolizumab are for the add-on maintenance treatment of severe CRSwNP in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, and for adult patients with inadequately control
- Zacks
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
- The Guardian
GSK boss warns UK life sciences at ‘tipping point’ despite Sunak’s R&D pledge
Emma Walmsley says ambition to be pharma superpower at risk unless improvements made in key areas
